Lowery, Ryan,Wilson, Jacob,Wells, Shawn,Underwood, Brian,Harding, Chistopher N.,Lacore, Terry
申请号：
AU2017253110
公开号：
AU2017253110A1
申请日:
2017.04.19
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds.
